Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

M6620

(adavosertib)

Phase 2Small molecule

Adavosertib is being studied as a cancer treatment that works by stopping cancer cells from repairing their DNA damage, making them more vulnerable to chemotherapy and radiation.[1] M6620 is currently being investigated across 15 indications[3], with its most advanced program in Phase 2.[1]

M6620 is one of 404 small molecule programs targeting Diffuse Intrinsic Pontine Glioma. It is currently in Phase 2.

15

Indications

28

Total Trials

10

Active Trials

403

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diffuse Intrinsic Pontine GliomaActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Endometrial Serous AdenocarcinomaActive, not recruiting

Uterine CancerActive, not recruiting

Fallopian Tube CancerActive, not recruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Prostate CancerActive, not recruiting

Ovarian CancerActive, not recruiting

GlioblastomaActive, not recruiting

Diffuse Intrinsic Pontine GliomaPhase 1

Active, not recruiting

Triple-Negative Breast CancerPhase 1

Active, not recruiting

Endometrial Serous AdenocarcinomaPhase 2

Active, not recruiting

Uterine CancerPhase 2

Active, not recruiting

Fallopian Tube CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

M6620

Tecentriq

Trodelvy

Avastin

BBio-Thera Solutions

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

DATROWAY

Voltaren

Lupron

EEastern Cooperative Oncology Group

Chirocaine

PPurdue Pharma LP

Tricor

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Patients With Advanced Solid Tumors

NCT04197713

Q4 2026

Phase 1Active, not recruiting

Clinical Stage III Esophageal Adenocarcinoma AJCC V8

NCT04460937

Phase 2Active, not recruiting

Fallopian Tube Cancer

NCT03579316

Phase 1Active, not recruiting

Primary Peritoneal Cancer

NCT02659241

Phase 2Active, not recruiting

Treatment

NCT04439227

Phase 2Active, not recruiting

Advanced Lymphoma

NCT02465060

Clinical

Trials by Indication[1]

Advanced Solid Tumors2 trials

A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00648648·206 enrolled

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03284385·60 enrolled

Fallopian Tube Cancer2 trials

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03579316·96 enrolled

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02101775·124 enrolled

Primary Peritoneal Cancer2 trials

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT02659241·38 enrolled

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02272790·95 enrolled

Advanced Solid Tumours2 trials

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT04949425·3 enrolled

Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04462952·6 enrolled

Tumor1 trial

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01827384·208 enrolled

19 more indications

Gemcitabine1 trial

Adavosertib and Gemcitabine in Advanced Pancreatic

Withdrawn·—·Phase 2·NCT05212025

Acute Myeloid Leukemia1 trial

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT02381548·20 enrolled

Ovarian Tumor1 trial

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01357161·136 enrolled

Uterine Cancer1 trial

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT03345784·10 enrolled

Cervical Cancer1 trial

A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT01076400·7 enrolled

Tics1 trial

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT04959266·5 enrolled

Serous Carcinoma1 trial

A Study of Adavosertib as Treatment for Uterine Serous Carcinoma

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04590248·109 enrolled

Glioblastoma1 trial

Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01849146·74 enrolled

Advanced Refractory Solid Tumors1 trial

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03253679·31 enrolled

Treatment1 trial

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04439227·35 enrolled

Prostate Cancer1 trial

Prostate Cancer Biomarker Enrichment and Treatment Selection

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03385655·200 enrolled

Absorption1 trial

Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT05008913·2 enrolled

Advanced Solid Tumor1 trial

A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT01047007·11 enrolled

Diffuse Intrinsic Pontine Glioma1 trial

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01922076·46 enrolled

Patients With Advanced Solid Tumors1 trial

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04197713·13 enrolled

Refractory Solid Tumors1 trial

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02095132·76 enrolled

Pediatric Cancer1 trial

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Preclinical·NCT02813135·472 enrolled

Advanced Lymphoma1 trial

Molecular Analysis for Therapy Choice (MATCH)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02465060·6,452 enrolled

Clinical Stage III Esophageal Adenocarcinoma AJCC v81 trial

A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04460937·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 28 trial records for adavosertib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — adavosertib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for adavosertib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Serine/threonine-Protein Kinase WEE1 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Related News